SAGE Therapeutics Inc to Review Topline Results from the Phase 3 WATERFALL Study Call Transcript
Good morning. Welcome to Sage Therapeutics' conference call to discuss top line results from the WATERFALL study. (Operator Instructions) This call is being webcast live on the Investors & Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics, and recording, reproduction or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Jeff Boyle, Vice President of Investor Relations at Sage.
Good morning, and thank you for joining Sage Therapeutics' conference call to discuss top line results from the WATERFALL study with zuranolone in major depressive disorder. Before we begin, I encourage everyone to go to the Investor & Media section of our website at sagerx.com, where you can find the press release related to today's call as well as slides that contain supplemental details.
I'll point out that we'll be making forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |